Matthew C. McDonough

合伙人

For more than a decade, Matthew C. McDonough has represented clients in securities class actions, financial services litigation, regulatory investigations, and an array of commercial litigation. Matt litigates in courts throughout the United States and before federal and state securities regulators.

  • Obtained summary judgment and permanent injunction for a broker-dealer preventing FINRA arbitration of securities claims (Oppenheimer & Co. Inc. v. Mitchell, 2024 WL 1492874 (W.D. Wash. Apr. 5, 2024)); decision affirmed on appeal to the Ninth Circuit (Oppenheimer & Co. Inc. v. Mitchell, 135 F.4th 837 (9th Cir. 2025))
  • Obtained summary judgment for Freddie Mac on securities fraud claims arising out of the subprime credit crisis
  • Obtained dismissal of all claims in putative securities class action against a publicly traded biopharmaceutical company and its officers and directors alleging false statements and omissions concerning the company’s CMC practices and New Drug Application (NDA) for a leading therapy
  • Obtained summary judgment for a paper company in dispute concerning postclosing obligations stemming from acquisition of paper mill (Resolute FP US Inc. v. New-Indy Catawba LLC, 2024 WL 5279797 (N.Y. Sup. Ct.))
  • Represented a hedge fund manager in connection with related SEC and DOJ investigations, federal court investor litigation, and Delaware Chancery books and records action
  • Represented a publicly held technology company and achieved dismissal of all Securities Act of 1933 strict liability claims arising out of initial public offering asserted against company and certain of its directors and officers in class action filed in Massachusetts state court
  • Represented a publicly held biopharmaceutical company and its current and former officers in an SEC investigation concerning the company’s public statements regarding the commercial viability of, and anticipated patient population for, principal drug candidate (no action taken by SEC)
  • Represented the underwriters of initial public offering of publicly held biopharmaceutical company in securities shareholder putative class actions and individual securities action; denial of motion for certification of state court class; dismissal with prejudice of federal individual action (Angelos v. Tokai Pharmaceuticals, Inc., et al., 494 F. Supp. 3d 39 (D. Mass. 2020))
  • Member of team that achieved successful resolution for a broker-dealer in more than 70 related FINRA customer arbitration matters involving allegations of fraud, breach of fiduciary duty, and RICO violations
  • Represented a broker-dealer in putative class action in Maine federal court alleging negligent misrepresentation and unfair trade practices in connection with representations concerning tax treatment of Section 529 education savings plan investment
  • Represented a broker-dealer in Minnesota state court action seeking to hold employer responsible for employee’s fraud
  • Represented a broker-dealer in related FINRA and Maine Office of Securities investigations concerning Section 529 education savings plan share class recommendations
  • Boston College Law School, 2014, J.D., magna cum laude, Order of the Coif
  • Boston College, 2011, B.A., magna cum laude
  • Massachusetts
  • Maine
  • New York
  • US Court of Appeals for the First Circuit
  • US District Court for the District of Massachusetts
  • US District Court for the District of Maine

Member, Best ETF Law Firm, ETF Express US Awards (2025)

Listed, The Best Lawyers in America, Ones to Watch, Commercial Litigation, Boston (2026)

Listed, The Best Lawyers in America, Ones to Watch, Litigation - Securities, Boston (2026)

Member, Law Firm of the Year, Securities Regulation, US News/Best Lawyers – Best Law Firms (2019)

Member, Boston Bar Association

Member, American Bar Association